CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare.
News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press release, the companies announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
The XDNA index has leading public companies who are developing in vivo gene editing technology.
The statement said:
Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases.
Barron’s covered the news by stating:
The week began with Germany’s Bayer (BAYN.Germany) saying on Sunday that it will pay $40 million, and potentially $1 billion more, to work with Mammoth BioSciences, a privately held venture co-founded by Jennifer Doudna—who won a Nobel Prize with Emmanuelle Charpentier for discovering the Crispr-Cas gene-editing technology. Monday, Pfizer unveiled a $1.3 billion partnership with the gene-editing firm Beam Therapeutics (BEAM).
To learn more about CRISPR & Gene Editing please visit the XDNA Index page or watch the video below: